Trial reportBMC cancer2026
Protocol for the internet-based lifestyle intervention to eradicate obese frailty in prostate cancer survivors (iLIVE) randomized controlled trial: a type I hybrid effectiveness implementation trial.
Trial report in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06011499 (Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors (iLIVE)
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundObese frailty is a growing national problem as trends towards aging and obesity converge. This problem is especially acute in men with prostate cancer treated with androgen deprivation therapy (ADT). ADT is the backbone of therapy for advanced prostate cancer, a disease which affects mostly older men. But, ADT accelerates muscle loss and gains in adiposity which threaten physical functioning and quality of life. Diet and resistance training may mitigate obese frailty but have rarely been combined in an accessible delivery format.
methodsThe Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors (iLIVE) Randomized Controlled Trial (RCT) aims to mitigate obese frailty among men with prostate cancer treated with ADT. Participants (N=250) are being recruited across North America to participate in this RCT that is implemented entirely over the internet. Eligibility criteria include body mass index >25 kg/m2 and > 2 frailty symptoms [illness, fatigue, inactivity, weakness, slowness]). Consented participants undergo assessments that include: online surveys (medical status, falls, physical activity, quality-of-life, healthcare utilization); dietary recalls (kilocalories, diet quality); body weight (Aria® scales); physical activity (Fitbits®); 4) internet-based physical performance (chair stand, timed up-and-go, gait speed tests); and 5) muscle mass (D3 creatine dilution). Participants are then randomized to one of two 6-month interventions: 1) Enhanced Usual Care (EUC): Encouraged to continue Aria® scale and Fitbit® use with monthly emails of publicly available diet- and exercise-related information; or 2) iLIVE: Same as EUC, plus website access to weekly serialized sessions on weight loss and diet quality and thrice-weekly live remote supervised group resistance training sessions. Assessments are repeated at 6-months; at 12-months, questionnaires are repeated and data from digital devices are captured. Intent-to-treat analysis will compare EUC vs. iLIVE (baseline-to-6-months) using a composite measure of obese frailty as the primary outcome. Designed as a type I hybrid-effectiveness implementation trial, data on intervention feasibility (including safety), acceptability, adoption, appropriateness, fidelity, sustainability, and cost are assessed, tracked, and analyzed. DISCUSSION: The iLIVE RCT is implemented exclusively over the internet and provides a blueprint for other highly scalable lifestyle interventions with potential for rapid translation into nationwide practice.
trial registrationClinicalTrials.gov: NCT06011499 (5.31.2025: https://clinicaltrials.gov/study/NCT06011499 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.